A tissue diagnosis is the diagnosis made when a piece of tissue is inspected by a pathologist, to analyze diseases based on tissues from organs and tumors.
The Tissue Diagnostics Market is expected to grow at a rate of ~7% by 2026. The rising prevalence of cancer and neoplastic cases, increasing demand for personalized medicines, evolving infrastructure for cancer diagnosis, technological advancement in tissue diagnostics, rising developments in consumables & instruments used in tissue diagnosis, and increasing demand for oncology screening are some of the key variables driving the worldwide tissue diagnostics market.
Mounting Adoption of Tissue Diagnostics for Early Detection & Screening of Cancer
Tissue-based diagnostic testing continues to serve as one of the gold standards for cancer diagnosis. No other technology can capture the disease’s biological context and the critical parameters that factor into patient outcomes. From a biopsy, a pathologist can decide the kind of cancer, the stage, and the degree to which cancer has invaded healthy tissue. Tissue diagnosis is viewed as a productive strategy for the clinical diagnosis of these diseases. The increased adoption of tissue diagnosis to understand the causes of cancer, identify targets for treatments, and discover biomarkers is expected to boost its tissue diagnostics market interest in the coming years.
Technological Advancements in Digital Pathology Fuels the Demand for Tissue Diagnostics Market
Digital pathology can help reduce human error as well as produce precise diagnostic results in a short turnaround time. The processes involved in digital pathology allow to speed up routine tasks without decreasing the quality of the execution of each task.
In June 2022, Roche announced the launch of its next-generation VENTANA DP 600 slide scanner. This slide scanner produces excellent image quality of stained histology slides from patient tissue samples
In May 2022, Leica Biosystems announced the launch of its compact, dual-retort tissue processor, the HistoCore PEGASUS Plus
Usage of Immunohistochemistry (IHC) Technology in Cancer Biomarker Research: Tissue Diagnostics Market
IHC is a massively popular tool used in cancer research. Various kinds of cancer are associated with specific protein biomarkers that can be identified via IHC that serve as a powerful tool to investigate tumor development and responses. Utilizing these techniques, researchers can identify the histogenesis of tumors, and stage tumors, predict tumor prognosis, and predict and monitor therapeutic response.
Explore Premium Report on Tissue Diagnostics Market @ https://meditechinsights.com/tissue-diagnostics-market/
North America Holds Major Market Share But APAC Expected to Witness Strong Growth
According to a geological viewpoint, North America as of now holds a major share in the global tissue diagnostics market. North America is supposed to keep on holding a major share in the coming years due to the rising prevalence of cancer, growing adoption of technologically advanced equipment and consumables, favorable reimbursement policies, and increasing awareness campaigns to minimize cancer incidence in the region.
Organic and Inorganic Growth Strategies Adopted by Players to Establish Their Foothold in the Market
Players operating in tissue diagnostics market are adopting organic and inorganic growth strategies such as collaborations, acquisitions, and new product launches to garner market share.
In February 2022, Labcorp announced the acquisition of Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics with a portfolio of comprehensive liquid biopsy and tissue-based products
In October 2021, Roche announced the launch of its AVENIO Tumor Tissue CGP Kit. The Kit complements the current CGP portfolio offered by Roche and Foundation Medicine and allows laboratories to expand their oncology research in-house
Competitive Landscape Analysis of Tissue Diagnostics Market
Some of the key players operating in the global tissue diagnostics market include Abbott Laboratories, F.Hoffmann-LA Roche Ltd, Danaher, Thermo Fisher Scientific, Agilent Technologies Inc., and Merck KGaA, among others.
For More Comprehensive Insights, Contact Us @ https://meditechinsights.com/contact-us/
About Medi-Tech Insights
Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services.
Associate, Medi-Tech Insights
+32 498 86 80 79